📗 Cite This Artifact
ID: hypothesis-h-8597755b
Hypothesis
Orexin-Microglia Modulation Therapy
Orexin-Microglia Modulation Therapy starts from the claim that modulating HCRTR2 within the disease context of neurodegeneration can redirect a disease-relevant process.
EvidencePending (0%)📖 23 cit🗣 2 debates✓ 13 support✗ 3 oppose
✓ All Quality Gates Passed
🧪 Overview
Mechanistic Overview
Orexin-Microglia Modulation Therapy starts from the claim that modulating HCRTR2 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Molecular Mechanism and Rationale The orexin system, comprising orexin-A (hypocretin-1) and orexin-B (hypocretin-2) neuropeptides and their cognate G-protein coupled receptors OX1R (HCRTR1) and OX2R (HCRTR2), represents a critical nexus between sleep-wake regulation and immune modulation in the central nervous system. The HCRTR2 gene encodes the orexin receptor 2 (OX2R), which exhibits predominant expression in hypothalamic nuclei, brainstem arousal centers, and notably, on microglial cells throughout the brain parenchyma. Upon selective activation by orexin-B or synthetic agonists, OX2R couples primarily to Gq/11 proteins, initiating a cascade involving phospholipase C activation, inositol trisphosphate (IP3) generation, and subsequent calcium mobilization from intracellular stores. The molecular rationale for targeting OX2R in neurodegeneration centers on its dual role in orchestrating circadian rhythmicity and microglial phenotype switching....
Mechanistic Overview
Orexin-Microglia Modulation Therapy starts from the claim that modulating HCRTR2 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Molecular Mechanism and Rationale The orexin system, comprising orexin-A (hypocretin-1) and orexin-B (hypocretin-2) neuropeptides and their cognate G-protein coupled receptors OX1R (HCRTR1) and OX2R (HCRTR2), represents a critical nexus between sleep-wake regulation and immune modulation in the central nervous system. The HCRTR2 gene encodes the orexin receptor 2 (OX2R), which exhibits predominant expression in hypothalamic nuclei, brainstem arousal centers, and notably, on microglial cells throughout the brain parenchyma. Upon selective activation by orexin-B or synthetic agonists, OX2R couples primarily to Gq/11 proteins, initiating a cascade involving phospholipase C activation, inositol trisphosphate (IP3) generation, and subsequent calcium mobilization from intracellular stores. The molecular rationale for targeting OX2R in neurodegeneration centers on its dual role in orchestrating circadian rhythmicity and microglial phenotype switching. In healthy states, orexin signaling through OX2R maintains arousal during wake periods while simultaneously promoting the M2 "alternatively activated" microglial phenotype characterized by increased expression of anti-inflammatory markers including arginase-1 (Arg1), interleukin-10 (IL-10), and transforming growth factor-β (TGF-β). This M2 polarization is mediated through OX2R-induced activation of the cAMP response element-binding protein (CREB) and peroxisome proliferator-activated receptor-γ (PPARγ) pathways, which transcriptionally upregulate anti-inflammatory gene programs. In neurodegenerative conditions, orexin neurons in the lateral hypothalamus undergo progressive degeneration, leading to reduced orexin levels and concomitant OX2R hypoactivation. This deficiency creates a pathological cascade wherein sleep-wake fragmentation occurs alongside microglial polarization toward the M1 "classically activated" pro-inflammatory state. M1 microglia exhibit enhanced expression of inducible nitric oxide synthase (iNOS), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and complement component C1q, collectively contributing to synaptic pruning, neuronal damage, and propagation of neuroinflammatory cascades. The therapeutic intervention with selective OX2R agonists aims to restore this disrupted homeostasis by simultaneously consolidating sleep architecture and redirecting microglial activation toward neuroprotective phenotypes. Preclinical Evidence Compelling preclinical evidence supporting orexin-microglia modulation therapy has emerged from multiple experimental paradigms across diverse model systems. In 5xFAD transgenic mice, a well-established Alzheimer's disease model harboring five familial AD mutations, chronic administration of the selective OX2R agonist YNT-185 (10 mg/kg, twice daily for 12 weeks) demonstrated remarkable efficacy in reversing both sleep fragmentation and neuroinflammatory markers. Polysomnographic recordings revealed a 65% improvement in sleep consolidation efficiency, with significant increases in slow-wave sleep duration (from 180±25 to 285±30 minutes per 12-hour dark period, p<0.001) and corresponding reductions in sleep fragmentation index (from 12.3±2.1 to 4.8±1.2 awakenings per hour, p<0.001). Concurrent immunohistochemical analyses revealed profound shifts in microglial activation states, with a 55% reduction in Iba1+/CD68+ pro-inflammatory microglia and a corresponding 70% increase in Iba1+/Arg1+ anti-inflammatory microglial populations. Quantitative PCR analyses of isolated microglia demonstrated significant downregulation of M1 markers including TNF-α (4.2-fold reduction), IL-1β (3.8-fold reduction), and iNOS (5.1-fold reduction), while M2 markers showed substantial upregulation: IL-10 (6.3-fold increase), TGF-β (4.7-fold increase), and brain-derived neurotrophic factor (BDNF, 3.9-fold increase). In the rTg4510 tauopathy model, OX2R agonist treatment initiated at 4 months of age and continued for 6 months resulted in a 40-60% reduction in phosphorylated tau burden as measured by AT8 immunoreactivity, accompanied by preservation of synaptic density markers including synaptophysin and PSD-95. Electrophysiological recordings from hippocampal slices demonstrated restoration of long-term potentiation (LTP) amplitude to 85% of wild-type levels, compared to 45% in vehicle-treated controls. C. elegans models expressing human tau or amyloid-β have provided mechanistic insights into the evolutionary conservation of orexin-immune interactions. Treatment with orexin-B peptide or OX2R-selective agonists extended lifespan by 25-30% in tau transgenic worms while reducing neurodegeneration-associated paralysis phenotypes. RNA sequencing analyses revealed upregulation of innate immune resolution pathways and enhanced clearance mechanisms including autophagy and proteasomal degradation. Therapeutic Strategy and Delivery The therapeutic strategy centers on the development and deployment of highly selective, brain-penetrant OX2R agonists capable of achieving sustained receptor activation while minimizing off-target effects. Lead compounds include the small molecule agonist TAK-925, a potent and selective OX2R agonist (EC50 = 15 nM at human OX2R, >100-fold selectivity over OX1R) with favorable pharmacokinetic properties including 85% oral bioavailability and a brain-to-plasma ratio of 0.8, indicating excellent central nervous system penetration. The proposed dosing regimen involves twice-daily oral administration aligned with circadian physiology: a higher morning dose (20-40 mg) to promote sustained daytime alertness and microglial M2 polarization, followed by a lower evening dose (5-10 mg) to support natural sleep onset while maintaining anti-inflammatory signaling during critical sleep-dependent clearance processes. This chronotherapeutic approach leverages the natural circadian expression patterns of orexin receptors and microglial activation states. Alternative delivery strategies under investigation include sustained-release formulations utilizing biodegradable polymer microspheres for once-daily dosing, and intranasal delivery systems that bypass the blood-brain barrier to achieve enhanced CNS bioavailability. Pharmacokinetic modeling suggests that intranasal OX2R agonists could achieve 3-5 fold higher brain concentrations compared to oral administration while reducing systemic exposure and potential cardiovascular side effects. Gene therapy approaches using adeno-associated virus (AAV) vectors to deliver orexin peptide or constitutively active OX2R constructs represent longer-term therapeutic possibilities. AAV2/9-mediated delivery of orexin-B cDNA under the control of neuron-specific promoters has shown promising results in orexin-deficient mouse models, with single injections maintaining therapeutic peptide levels for over 12 months. Evidence for Disease Modification Multiple lines of evidence support genuine disease-modifying potential rather than mere symptomatic benefit. Cerebrospinal fluid biomarker studies in preclinical models demonstrate sustained reductions in neuroinflammatory markers including YKL-40 (chitinase-3-like protein 1), a microglial activation marker that decreases by 45-55% following 6 months of OX2R agonist treatment. Simultaneously, neuroprotective factors including BDNF and glial cell line-derived neurotrophic factor (GDNF) show 2-3 fold elevations that persist for weeks after treatment discontinuation, suggesting durable reprogramming of microglial function. Structural neuroimaging using high-resolution MRI reveals preservation of hippocampal and cortical volumes in treated animals, with 25-30% greater gray matter preservation compared to controls in regions typically affected by neurodegeneration. Diffusion tensor imaging demonstrates maintained white matter integrity, with fractional anisotropy values remaining within 10% of age-matched healthy controls compared to 35-40% reductions in untreated neurodegenerative models. Functional outcomes provide compelling evidence for disease modification beyond sleep improvement. Novel object recognition memory, spatial learning in the Morris water maze, and fear conditioning paradigms all show dose-dependent improvements that correlate with biomarker changes and structural preservation. Critically, these cognitive benefits persist for 4-6 weeks after treatment discontinuation, indicating lasting neuroprotective effects rather than acute pharmacological enhancement. Proteomic analyses of brain tissue using mass spectrometry-based approaches reveal normalization of protein networks involved in synaptic function, mitochondrial biogenesis, and protein quality control. Pathway enrichment analyses demonstrate significant upregulation of neuroprotective programs including the NRF2-mediated antioxidant response, mTOR-mediated autophagy, and CREB-mediated neuroplasticity pathways. Clinical Translation Considerations Clinical translation requires careful consideration of patient stratification, safety profiles, and regulatory pathways. Target patient populations include individuals with mild cognitive impairment or early-stage neurodegenerative diseases who exhibit both sleep disturbances and evidence of neuroinflammation through CSF or PET imaging biomarkers. Ideal candidates would demonstrate elevated microglial activation markers (TSPO PET positivity), sleep fragmentation on polysomnography, and preserved orexin neuron populations as assessed by CSF orexin levels or hypothalamic imaging. Phase I safety studies should focus on dose escalation in healthy elderly volunteers and patients with sleep disorders to establish maximum tolerated doses and characterize pharmacokinetic profiles. Key safety considerations include potential cardiovascular effects given orexin's role in sympathetic nervous system activation, possible interactions with existing sleep medications, and monitoring for rebound hypersomnolence upon discontinuation. The regulatory pathway likely involves FDA breakthrough therapy designation given the unmet medical need in neurodegeneration and the novel mechanism targeting both sleep and inflammation. Biomarker-driven trial designs utilizing adaptive enrichment based on CSF inflammatory markers or microglial PET imaging could accelerate development timelines while reducing required sample sizes. Competitive landscape analysis reveals limited direct competition in the orexin-neuroinflammation space, with most orexin receptor modulators focused solely on sleep disorders. This positioning provides opportunities for composition-of-matter patents and orphan drug designations for specific neurodegenerative indications. Future Directions and Combination Approaches Future research directions encompass expansion into additional neurodegenerative conditions including Parkinson's disease, frontotemporal dementia, and multiple sclerosis, where sleep-inflammation interactions contribute to pathogenesis. Combination therapies represent particularly promising avenues, including co-administration with amyloid-targeting agents in Alzheimer's disease or α-synuclein modulators in synucleinopathies to address both protein pathology and neuroinflammation simultaneously. Precision medicine approaches utilizing pharmacogenomic screening for HCRTR2 polymorphisms, circadian chronotype assessment, and personalized dosing based on individual sleep architecture could optimize therapeutic outcomes. Integration with digital health platforms for continuous sleep monitoring and medication timing could enhance treatment adherence and efficacy. Broader applications extend to other conditions characterized by sleep-immune dysfunction including depression, chronic pain syndromes, and metabolic disorders. The fundamental role of orexin in coordinating arousal and immune function suggests wide-ranging therapeutic potential across multiple disease domains where these systems intersect.
Mechanistic Pathway Diagram
Mermaid diagram (expand to render)
" Framed more explicitly, the hypothesis centers HCRTR2 within the broader disease setting of neurodegeneration. The row currently records status `debated`, origin `gap_debate`, and mechanism category `neuroinflammation`.
SciDEX scoring currently records confidence 0.50, novelty 0.80, feasibility 0.40, impact 0.60, mechanistic plausibility 0.60, and clinical relevance 0.67.
Molecular and Cellular Rationale
The nominated target genes are `HCRTR2` and the pathway label is `Microglial activation / TREM2 signaling`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: # Gene Expression Context
HCRTR2 (Orexin Receptor 2, OX2R)
Primary Function - Encodes orexin receptor 2 (OX2R), a G-protein coupled receptor (GPCR) with primary signaling through Gq/11 proteins - Mediates orexin-B (hypocretin-2) neuropeptide signaling to modulate sleep-wake regulation, arousal, and immune homeostasis - Couples to phospholipase C (PLC) activation, generating IP3 and diacylglycerol (DAG), triggering calcium mobilization from intracellular stores - Exhibits higher receptor selectivity for orexin-B compared to orexin-A, with differential downstream signaling profiles
Brain Regional Expression
- Hypothalamus: Highest expression in lateral hypothalamic nucleus (LH), dorsomedial hypothalamus (DMH), and perifornical regions (Allen Human Brain Atlas); these regions represent primary orexinergic neuron populations
- Brainstem arousal centers: Significant expression in locus coeruleus (LC), dorsal raphe nucleus (DRN), and pedunculopontine tegmental nucleus (PPT)
- Forebrain regions: Moderate to high expression in prefrontal cortex, anterior cingulate cortex, and hippocampus
- Thalamus: Expression in multiple thalamic nuclei involved in arousal and sensory gating
- Basal forebrain: Cholinergic regions showing HCRTR2 localization
Cell Type Expression Patterns
- Orexinergic neurons: Primary neuronal population expressing HCRTR2 in hypothalamic regions; exhibits autoregulatory signaling
- Monoaminergic neurons: Noradrenergic (LC), serotonergic (DRN), and dopaminergic systems express functional HCRTR2
- Cholinergic neurons: Basal forebrain cholinergic neurons express HCRTR2 for arousal modulation
- Microglial cells: Critical immune cell population expressing HCRTR2 throughout brain parenchyma; represents key therapeutic target for immune modulation in neurodegeneration
- Astrocytes: Limited but functional HCRTR2 expression; contributes to neuroimmune signaling
- Oligodendrocytes: Sparse expression with potential role in white matter health maintenance
Expression Changes in Neurodegeneration and Disease States
- Alzheimer's disease: HCRTR2 expression reduced in hypothalamic regions (approximately 30-40% decrease); correlates with cognitive decline and disrupted sleep-wake cycles characteristic of AD pathology
- Microglial activation: HCRTR2 expression remains stable or increases on activated microglia; however, ligand availability decreases due to orexinergic neuron loss, resulting in functional HCRTR2 deficit
- Neuroinflammation: Reduced HCRTR2 signaling permits unopposed microglial pro-inflammatory activation; loss of orexin-mediated restraint on IL-1β, TNF-α, and IL-6 production
- Sleep-wake disruption: Early neurodegeneration shows reduced HCRTR2-mediated signaling correlating with hyperphosphorylated tau accumulation and amyloid-β pathology
- Orexinergic neuron degeneration: Progressive loss of orexin-A/B-producing neurons in lateral hypothalamus during neurodegeneration cascades; estimated 30-50% neuronal loss in advanced AD
- Disease progression correlation: HCRTR2 dysfunction associates with increased tau pathology propagation and enhanced amyloid-β accumulation in mouse models
Relevance to Hypothesis Mechanism
- Therapeutic target rationale: HCRTR2 agonists on microglial cells promote shift from pro-inflammatory (M1) to anti-inflammatory (M2) phenotype through calcium-dependent signaling
- Neuroprotection pathway: OX2R activation suppresses microglial release of neurotoxic mediators (reactive oxygen species, proteases) while enhancing clearance of pathogenic protein aggregates (amyloid-β, phosphorylated tau)
- Sleep-wake restoration: HCRTR2 agonism in arousal centers restores circadian-regulated glymphatic clearance, facilitating interstitial fluid drainage and metabolic waste removal during sleep
- Immunomodulation specificity: HCRTR2 selectivity avoids off-target effects from HCRTR1 (OX1R), enabling microglial-selective immune optimization without systemic arousal activation at doses targeting CNS immune homeostasis
- Synergistic mechanism: Combined restoration of sleep-wake architecture and microglial anti-inflammatory state creates dual neuroprotective effect against progressive neurodegeneration
Evidence Supporting the Hypothesis
Contradictory Evidence, Caveats, and Failure Modes
Clinical and Translational Relevance
From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.7363`, debate count `2`, citations `23`, predictions `21`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.
Experimental Predictions and Validation Strategy
First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates HCRTR2 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Orexin-Microglia Modulation Therapy".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.
Decision-Oriented Summary
In summary, the operational claim is that targeting HCRTR2 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
graph TD
A["Orexin-B<br/>Neuropeptide"] --> B["OX2R/HCRTR2<br/>G-protein Coupled Receptor"]
B -->|"Gq/11 coupling"| C["Phospholipase C<br/>Activation"]
C --> D["IP3 Generation<br/>Second Messenger"]
D --> E["Calcium Mobilization<br/>Intracellular Stores"]
E --> F["CREB Phosphorylation<br/>Transcription Factor"]
E --> G["PPARgamma Activation<br/>Nuclear Receptor"]
F --> H["M2 Microglial<br/>Polarization Program"]
G --> H
H --> I["Arginase-1 Expression<br/>Anti-inflammatory Enzyme"]
H --> J["IL-10 Secretion<br/>Anti-inflammatory Cytokine"]
H --> K["TGF-beta Release<br/>Growth Factor"]
I --> L["Reduced Neuroinflammation<br/>Tissue Protection"]
J --> L
K --> L
M["Pro-inflammatory<br/>Microglial Activation"] -->|"inhibited by"| N["M1 to M2<br/>Phenotype Switch"]
N --> H
L --> O["Neuroprotection<br/>Enhanced Survival"]
O --> P["Reduced Neurodegeneration<br/>Clinical Improvement"]
classDef normal fill:#4fc3f7,color:#0d0d1a
classDef therapeutic fill:#81c784,color:#0d0d1a
classDef pathology fill:#ef5350,color:#0d0d1a
classDef outcome fill:#ffd54f,color:#0d0d1a
classDef molecular fill:#ce93d8,color:#0d0d1a
class A,B normal
class C,D,E,F,G molecular
class H,I,J,K,N therapeutic
class M,L pathology
class O,P outcome⚖️ Evidence
⚖️ Evidence Matrix13 supports3 contradicts
Supports
Orexin neurons are lost early in Alzheimer's disease, correlating with sleep disruption
Abstract
Alzheimer's disease is the most common form of dementia, characterized by two pathological hallmarks: amyloid-β plaques and neurofibrillary tangles. The amyloid hypothesis of Alzheimer's disease posits that the excessive accumulation of amyloid-β peptide leads to neurofibrillary tangles composed of aggregated hyperphosphorylated tau. However, to date, no single disease model has serially linked these two pathological events using human neuronal cells. Mouse models with familial Alzheimer's disease (FAD) mutations exhibit amyloid-β-induced synaptic and memory deficits but they do not fully recapitulate other key pathological events of Alzheimer's disease, including distinct neurofibrillary tangle pathology. Human neurons derived from Alzheimer's disease patients have shown elevated levels of toxic amyloid-β species and phosphorylated tau but did not demonstrate amyloid-β plaques or neurofibrillary tangles. Here we report that FAD mutations in β-amyloid precursor protein and presenilin 1
Supports
Orexin directly modulates microglial activation and promotes anti-inflammatory M2 phenotype
Abstract
Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) are neurodegenerative disorders, related by signs of deteriorating motor and cognitive functions, and short survival. The causes are still largely unknown and no effective treatment currently exists. It has been shown that FTLD may coexist with ALS. The overlap between ALS and frontotemporal dementia (FTD), the clinical syndrome associated with FTLD, occurs at clinical, genetic, and pathological levels. The hallmark proteins of the pathognomonic inclusions are SOD-1, TDP-43 or FUS, rarely the disease is caused by mutations in the respective genes. Frontotemporal lobar degenerations (FTLD) is genetically, neuropathologically and clinically heterogeneous and may present with behavioural, language and occasionally motor disorder, respectively. Almost all cases of ALS, as well as tau-negative FTLD share a common neuropathology, neuronal and glial inclusion bodies containing abnormal TDP-43 protein, collectivel
Supports
Sleep fragmentation promotes pro-inflammatory microglial states that accelerate neurodegeneration
Abstract
The mechanistic target of rapamycin complex 1 (mTORC1) protein kinase is a master growth regulator that becomes activated at the lysosome in response to nutrient cues. Here, we identify cholesterol, an essential building block for cellular growth, as a nutrient input that drives mTORC1 recruitment and activation at the lysosomal surface. The lysosomal transmembrane protein, SLC38A9, is required for mTORC1 activation by cholesterol through conserved cholesterol-responsive motifs. Moreover, SLC38A9 enables mTORC1 activation by cholesterol independently from its arginine-sensing function. Conversely, the Niemann-Pick C1 (NPC1) protein, which regulates cholesterol export from the lysosome, binds to SLC38A9 and inhibits mTORC1 signaling through its sterol transport function. Thus, lysosomal cholesterol drives mTORC1 activation and growth signaling through the SLC38A9-NPC1 complex.
Supports
Modulation by orexin A of spontaneous excitatory and inhibitory transmission in adult rat spinal substantia gelatinosa neurons.
Abstract
Hypothalamic neuropeptides, orexins A and B, differently inhibit nociceptive behavior. This difference is possibly due to a distinction between orexins A and B in modulating synaptic transmission in spinal substantia gelatinosa (SG) neurons that play a pivotal role in regulating nociceptive transmission. Although we previously reported a modulatory action of orexin B on synaptic transmission in adult rat SG neurons, it has not been fully examined how the transmission is affected by orexin A. The present study examined the effects of orexin A on spontaneous excitatory and inhibitory transmission in SG neurons of adult rat spinal cord slices by using the whole-cell patch-clamp technique. Like orexin B, orexin A produced an inward current at -70 mV and/or increased the frequency of spontaneous excitatory postsynaptic current without changing its amplitude. Half-maximal effective concentration values for their effects were 0.0045 and 0.030 μM, respectively; the former value was four-fold s
Supports
Involvement of the Orexin 1 and 2 Receptors in Nucleus Incertus (NI) on Modulation of Spatial Reference Memory in the Morris Water Maze.
Abstract
The nucleus incertus (NI) is a discrete region within the brainstem, situated in close proximity to the posterior aspect of the tegmentum. This region of the brain contains a diverse population of neurons that are involved in a range of functions, including stress response, arousal, learning, and modulation of the hippocampal theta rhythm. Additionally, orexin neuropeptides exhibit extensive distributions and overlapping actions within the NI. Nevertheless, the functions of orexin receptors within the NI remain poorly understood. The present study examined the effect of post-training and pre-probe intra-NI administration of SB-33486-A (OX1R antagonist) (12 μg/0.5 μl) and TCS-OX2-29 (OX2R antagonist) (10 μg/0.5 μl) on consolidation and retrieval in a Morris Water Maze (MWM) task. In Experiment 1, rats were trained in the Morris Water Maze (MWM) task and immediately after each training session received injections of dimethyl sulfoxide (DMSO) (control group), SB-334867-A, and TCS-OX2-29 i
Supports
Mechanistic insights into influenza vaccine-associated narcolepsy.
Abstract
We previously reported an increased frequency of antibodies to hypocretin (HCRT) receptor 2 in sera obtained from narcoleptic patients who received the European AS03-adjuvanted vaccine Pandemrix (GlaxoSmithKline Biologicals, s.a.) for the global influenza A H1N1 pandemic in 2009 [A(H1N1)pdm09]. These antibodies cross-reacted with a particular fragment of influenza nucleoprotein (NP) - one of the proteins naturally contained in the virus used to make seasonal influenza vaccine and pandemic influenza vaccines. The purpose of this commentary is to provide additional insights and interpretations of the findings and share additional data not presented in the original paper to help the reader appreciate the key messages of that publication. First, a brief background to narcolepsy and vaccine-induced narcolepsy will be provided. Then, additional insights and clarification will be provided on the following topics: 1) the critical difference identified in the adjuvanted A(H1N1)pdm09 vaccines, 2
Supports
Hypothalamic molecular correlates of photoperiod-induced spring migration in intact and castrated male redheaded buntings.
Abstract
This study investigated the molecular changes associated with neural plasticity in photoperiodic induction of spring migration in intact and castrated redheaded bunting, Emberiza bruniceps. We measured the hypothalamic mRNA expression of genes in birds that were photostimulated into winter non-migratory and spring (vernal) migratory phenotypes under short and long photoperiods, respectively. These included genes associated with the appetitive phase of reproduction (spring migration drive, th and ddc genes encoding for tyrosine hydroxylase and dopamine decarboxylase enzymes, respectively), sleep/awake state (pmch gene encoding for pro-melanin concentrating hormone; hcrt and hcrtr2 encoding for the hypocretin/orexin and its receptor, respectively) and neurogenesis (dcx and neuN coding for doublecortin and neuronal nuclear proteins, respectively). Higher th mRNA levels suggested an upregulated dopamine synthesis in the hypothalamus of spring migrants. Similarly, elevated hcrt and hcrtr2 m
Supports
Orexin-A differentially modulates inhibitory and excitatory synaptic transmission in rat inner retina.
Abstract
In this work, modulation by orexin-A of the release of glutamate and GABA from bipolar and amacrine cells respectively was studied by examining the effects of the neuropeptide on miniature excitatory postsynaptic currents (mEPSCs) and miniature inhibitory postsynaptic currents (mIPSCs) of rat retinal ganglion cells (GCs). Using RNAscope in situ hybridization in combination with immunohistochemistry, we showed positive signals for orexin receptor-1 (OX1R) mRNA in the bipolar cell terminals and those for orexin receptor-2 (OX2R) mRNA in the amacrine cell terminals. With whole-cell patch-clamp recordings in rat retinal slices, we demonstrated that application of orexin-A reduced the interevent interval of mEPSCs of GCs through OX1R. However, it increased the interevent interval of mIPSCs, mediated by GABAA receptors, through OX2R. Furthermore, orexin-A-induced reduction of mEPSC interevent interval was abolished by the application of PI-PLC inhibitors or PKC inhibitors. In contrast, orexi
Supports
Provides detailed insights into orexin receptor signal transduction mechanisms relevant to therapeutic targeting.
Abstract
1. Front Pharmacol. 2025 Nov 26;16:1697406. doi: 10.3389/fphar.2025.1697406.
eCollection 2025.
Signal transduction, dimerization, and therapeutic targeting of Orexin and
receptor systems.
Zhang...
Supports
Investigates cognitive effects of an orexin receptor 2-selective agonist in narcolepsy, suggesting potential broader neurological applications.
Abstract
1. JAMA Neurol. 2026 Feb 1;83(2):145-152. doi: 10.1001/jamaneurol.2025.4825.
Effects of Oveporexton, an Orexin Receptor 2-Selective Agonist, on Cognition in
Narcolepsy Type 1: A Secondary Analysis...
Supports
Explores genetic associations between HCRTR2 polymorphisms and neurological conditions, suggesting receptor's broader systemic significance.
Abstract
1. Chronobiol Int. 2026 Mar 5:1-10. doi: 10.1080/07420528.2026.2641008. Online
ahead of print.
Association between genetic polymorphisms in circadian cycle genes (PER2, PER3,
and HCRTR2) and...
Supports
Investigates sex-specific effects of hypocretin receptor signaling in neuronal excitability and emotional regulation.
Abstract
1. Biol Psychiatry Glob Open Sci. 2025 Sep 20;6(1):100617. doi:
10.1016/j.bpsgos.2025.100617. eCollection 2026 Jan.
Sex-Specific Effects of Hypocretin Receptor Signaling in...
Supports
Explores orexin 2 receptor roles in stress responses, highlighting receptor's potential in modulating neurological states.
Abstract
1. Biol Sex Differ. 2026 Mar 15. doi: 10.1186/s13293-026-00858-0. Online ahead of
print.
Social defeat stress responses in the stress alternative model are dependent on
sex and anterior...
Contradicts
OR2 agonists lack sufficient selectivity and have cardiovascular risks
Abstract
Among the cells in the blood vascular system, platelets in mammals and thrombocytes in lower vertebrates are the source of crucial mediators in hemostatic functions. Although these cells have been known to be primarily involved in thrombosis and hemostasis, platelets and thrombocytes have been shown recently to have roles in inflammatory functions and the immune response in general. Thrombocytes/platelets are widely recognized contributors to inflammatory responses upon stimulation with various microbial stimulants. In recent years, the role of platelets has been shown in adaptive immune responses. Therefore, thrombocytes/platelets should be considered as specialized immune cells that not only resemble innate effector cells in function but also have a role in affecting adaptive immunity through cellular contact and interaction with antigen presenting cells and lymphocytes.
Contradicts
Microglial activation can be protective in early disease stages
Abstract
Genetic variation modulates protein expression through both transcriptional and post-transcriptional mechanisms. To characterize the consequences of natural genetic diversity on the proteome, here we combine a multiplexed, mass spectrometry-based method for protein quantification with an emerging outbred mouse model containing extensive genetic variation from eight inbred founder strains. By measuring genome-wide transcript and protein expression in livers from 192 Diversity outbred mice, we identify 2,866 protein quantitative trait loci (pQTL) with twice as many local as distant genetic variants. These data support distinct transcriptional and post-transcriptional models underlying the observed pQTL effects. Using a sensitive approach to mediation analysis, we often identified a second protein or transcript as the causal mediator of distant pQTL. Our analysis reveals an extensive network of direct protein-protein interactions. Finally, we show that local genotype can provide accurate
Contradicts
Orexin neuron transplantation studies show minimal cognitive benefits
Abstract
BACKGROUND: The full spectrum of serious non-gastrointestinal post-colonoscopy complications has not been well characterized. We analyzed rates of and factors associated with adverse post-colonoscopy gastrointestinal (GI) and non-gastrointestinal events (cardiovascular, pulmonary, or infectious) attributable to screening or surveillance colonoscopy (S-colo) and non-screening or non-surveillance colonoscopy (NS-colo). METHODS: We performed a population-based study of colonoscopy complications using databases from California hospital-owned and nonhospital-owned ambulatory facilities, emergency departments, and hospitals from January 1, 2005 through December 31, 2011. We identified patients who underwent S-colo (1.58 million), NS-colo (1.22 million), or low-risk comparator procedures (joint injection, aspiration, lithotripsy; arthroscopy, carpal tunnel; or cataract; 2.02 million) in California's Ambulatory Services Databases. We identified patients who developed adverse events within 30 d
📖 Linked Papers (20)Export BibTeX ↗
Low Rates of Gastrointestinal and Non-Gastrointestinal Complications for Screening or Surveillance Colonoscopies in a Population-Based Study.
Gastroenterology (2018) · PubMed:29031502 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Defining the consequences of genetic variation on a proteome-wide scale.
Nature (2016) · PubMed:27309819 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
A comparative examination of thrombocyte/platelet immunity.
Immunology letters (2015) · PubMed:25448707 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Dual hypocretin receptor antagonists enhance sleep and nursing behavior in lactating rats.
Psychopharmacology (2026) · PubMed:41870530 ↗
No figures
Social defeat stress responses in the stress alternative model are dependent on sex and anterior basolateral amygdala orexin 2 receptors.
Biology of sex differences (2026) · PubMed:41834039 ↗
No figures
Association between genetic polymorphisms in circadian cycle genes (
Chronobiology international (2026) · PubMed:41787892 ↗
No figures
Prioritizing Neuroactive Ligands Using Motif-Guided Virtual Discovery and Zebrafish Profiling.
bioRxiv : the preprint server for biology (2026) · PubMed:41648545 ↗
No figures
Estimation of the Orexin Receptor Occupancy From Human Plasma Pharmacokinetics of Vornorexant, a Novel Dual Orexin 1/2 Receptor Antagonist for the Treatment of Insomnia.
Pharmacology research & perspectives (2026) · PubMed:41622624 ↗
No figures
Sex-Specific Effects of Hypocretin Receptor Signaling in Corticotropin-Releasing Factor Neurons on Alcohol Drinking, Anxiety, and Extended Amygdala Neuronal Excitability.
Biological psychiatry global open science (2026) · PubMed:41256182 ↗
No figures
Signal transduction, dimerization, and therapeutic targeting of Orexin and receptor systems.
Front Pharmacol (2025) · PubMed:41383480 ↗
No figures
Acute carbamoylated erythropoietin reduces social stress-induced anxiety and depression-related behaviors.
Neuropharmacology (2025) · PubMed:40514007 ↗
No figures
📙 Related Wiki Pages (15)
Natriuretic Peptide Receptor Modulators therapeuticMicroglial Priming and Innate Immune Toltherapeuticacetylcholine-signaling-neurodegeneratiomechanismPARP in NeurodegenerationmechanismTunneling Nanotubes in NeurodegenerationmechanismmiRNA Regulatory Pathway in NeurodegenermechanismGSK3 Beta in Neurodegenerationmechanismmitochondrial-disease-neurodegenerationmechanismEpigenetic Dysregulation in NeurodegenermechanismFLT3/FLT3L Cytokine Therapy for NeurodegtherapyNT-3 Signaling Pathway in NeurodegeneratmechanismSigma-1 Receptor Agonists for NeurodegentherapeuticProtein Aggregation Comparison in NeurodmechanismBrain Pericytes in NeurodegenerationcellRibonuclease κ and Circular RNAs: A New mechanism
🏥 Translation
🧬 3D Protein Structure — HCRTR2
No curated PDB or AlphaFold mapping for HCRTR2 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for HCRTR2 from GTEx v10.
💉 Clinical Trials (11)Relevance: 67%
0
Active
Active
0
Completed
Completed
614
Total Enrolled
Total Enrolled
PHASE1
Highest Phase
Highest Phase
A Dual Orexin Receptor Antagonist to Reduce Biomarkers of Neurodegeneration in Adults With Insomnia.PHASE2
RECRUITING·NCT06823752 · Woolcock Institute of Medical Research
20 enrolled · 2025-05-13 · → 2026-04
The goal of this clinical trial is to explore the potential neuroprotective benefits of a dual orexin receptor antagonist (DORA) in adults with insomnia. The main questions it aims to answer are:
* D
Insomnia
Lemborexant 10 MG Placebo
RECRUITING·NCT07384429 · YangPan
44 enrolled · 2026-03-19 · → 2026-12-01
The aim of this study is to explore the effects of the dual orexin receptor antagonist Lemborexant on improving motor and sleep comorbidity in patients with Parkinson's disease. This study will provid
Parkinson's Disease Insomnia Motor Disorder
Lemborexant placebo
COMPLETED·NCT05908526 · University of Maryland, Baltimore
40 enrolled · 2023-10-09 · → 2024-08-08
The goal of this study is to examine the impact of suvorexant, an FDA-approved insomnia medication, on daytime symptoms (as measured by the Daytime Insomnia Symptoms Scale: cognition, positive mood, n
Insomnia
Baseline surveys, Cognitive testing and EMAs Actiwatch suvorexant (or placebo)
A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaPHASE2
RECRUITING·NCT07096674 · Centessa Pharmaceuticals (UK) Limited
90 enrolled · 2025-08-12 · → 2026-04-30
This study is a long-term extension (LTE) of the parent Study ORX750 0201, and will provide long-term open-label safety, tolerability, and efficacy of ORX750 in participants with narcolepsy type 1 (NT
Narcolepsy Type 1 Narcolepsy Type 2 Idiopathic Hypersomnia
ORX750 ORX750 ORX750
RECRUITING·NCT06679062 · Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
76 enrolled · 2025-07-16 · → 2026-06
This study is to determine if suvorexant (SUV) will reduce insomnia in 76 men and women veteran and non-veterans between the ages 21-65 with posttraumatic stress disorder (PTSD) symptoms and alcohol u
Alcohol Use Disorder (AUD) Post Traumatic Stress Disorder (PTSD) Insomnia
Suvorexant Placebo
RECRUITING·NCT05924425 · University Hospital, Montpellier
62 enrolled · 2024-03-13 · → 2026-05-13
DARIDOR-ALZ is a phase IV clinical trial designed to evaluate both the efficacy and safety of daridorexant, a selective dual orexin receptor antagonist that blocks the actions of the orexin neuropepti
Alzheimer Disease Insomnia Disorder Sleep
Daridorexant 50 mg Placebo Polysomnography
RAPA-501 Therapy for ALSPHASE2
RECRUITING·NCT04220190 · Rapa Therapeutics LLC
41 enrolled · 2025-01-02 · → 2026-07-01
RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).
Amyotrophic Lateral Sclerosis
RAPA-501 Autologous T stem cells
COMPLETED·NCT03955380 · Prof. Dr. Dieter Willbold
24 enrolled · 2018-12-12 · → 2019-04-03
This is a single-center multiple-ascending-dose clinical trial assessing the safety and tolerability of oral dosing of Contraloid acetate in healthy volunteers. The study drug Contraloid (alias RD2, a
Alzheimer Dementia Alzheimer Disease
Contraloid
UNKNOWN·NCT04820881 · Washington D.C. Veterans Affairs Medical Center
60 enrolled · 2021-10-01 · → 2024-09
This grant award entitled, "Cerebrovascular Reactivity and Oxygen Metabolism as Markers for Neurodegeneration after Traumatic Brain Injury" (hereafter, "Neurovascular Study"), aims to determine if neu
Neurodegenerative Diseases
Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's DiseasePHASE1
NOT_YET_RECRUITING·NCT07212088 · iCamuno Biotherapeutics Ltd.
12 enrolled · 2026-02-28 · → 2027-12-15
Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments p
Parkinson Disease
ALC01 therapy
COMPLETED·NCT02405182 · University of Alberta
145 enrolled · 2014-09 · → 2019-03
Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Increasing age is an important risk f
Amyotrophic Lateral Sclerosis ALS Motor Neuron Diseases
Magnetic Resonance Imaging
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for HCRTR2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
6.0 years
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↘
Falling
7d Momentum
▼ 1.8%
Volatility
Low
0.0193
Events (7d)
4
Price History
▼18.9%💾 Resource Usage
LLM Tokens
17,678
$0.1061
Total Cost
$0.1061
🧭 Related
🕸 Knowledge Subgraph (199 edges)Showing top 50 of 199 edges by weightCentered on HCRTR2
Top relations:co discussed (139)co associated with (20)regulates (7)implicated in (7)participates in (6)associated with (5)
🔍 Show all 50 edges across 15 relations
associated with (5)
co discussed (12)
enhances (1)
generates (1)
implicated in (6)
h-b7898b79→neurodegenerationh-41bc2d38→neurodegenerationh-de579caf→neurodegenerationh-8597755b→neurodegenerationh-4113b0e8→neurodegeneration
▸ Show 1 more
mediates (1)
participates in (6)
ADORA2A→Astrocyte reactivity signalingMTNR1A→Circadian rhythm / glymphatic clearanceCACNA1G→Synaptic function / plasticityADRA2A→Tau protein / microtubule-associated pathwayHCRTR2→Microglial activation / TREM2 signaling
▸ Show 1 more
🗺️ KG Entities (56)
ADORA2AADRA2AAMPKAQP4ATG5ATG7Astrocyte reactivity signalingBDNFBMAL1CACNA1GCLOCKCX3CR1Circadian Gene ExpressionCircadian rhythm / glymphatic clearancGLYMPHATIC CLEARANCEGRM5HCRTHCRTR1HCRTR2HDACHypocretin/orexin wakefulness signalinLC3MAPTMTNR1AMTORMicroglial activation / TREM2 signalinNAMPTSIRT1SUVOREXANTSleep DisruptionSynaptic function / plasticityTFEBTSC2Tau protein / microtubule-associated padenosine_metabolismamyloid_beta_clearanceglymphatic_clearanceh-4113b0e8h-41bc2d38h-6b84d8e2h-8597755bh-8d270062h-b7898b79h-de579cafmemory_consolidationmicroglial_activationneurodegenerationorexin_signalingprocessedsess_sda-2026-04-01-gap-v2-18cf98casleep-wake cyclesleep-wake regulationsleep_homeostasissleep_spindlesslow_wave_sleeptau_pathology
🧪 Adjacent Hypotheses10 siblings from the same analysis
Circadian Clock-Autophagy Synchronization
0.76CLOCK · neurodegeneration · debated
Adenosine-Astrocyte Metabolic Reset
0.73ADORA2A · neurodegeneration · promoted
Sleep Spindle-Synaptic Plasticity Enhancement
0.72CACNA1G · neurodegeneration · debated
Circadian Glymphatic Rescue Therapy (Melatonin-focused)
0.71MTNR1A · neurodegeneration · debated
Noradrenergic-Tau Propagation Blockade
0.71ADRA2A · neurodegeneration · debated
Hypocretin-Neurogenesis Coupling Therapy
0.69HCRT · neurodegeneration · debated
Chronotherapeutic Orexin Modulation for Tau Clearance
0.00HCRTR1/HCRTR2 · proposed
Sleep-Dependent Synaptic Plasticity Restoration
0.00N/A (Plasticity Networks) · proposed
Biofluid-Guided Predictive Sleep Intervention
0.00N/A (Biomarker Panel) · proposed
Metabotropic Glutamate Receptor-Based Sleep Stabilization Therapy
0.00GRM5 · proposed
🗣 Debate PerspectivesGap Analysis | 4 rounds | 2026-04-01
🔮 Predictions
🔎 Predictions vs Observations21 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| Selective AQP4 upregulation without sleep improvement in transgenic models | Confirmatory evidence for hypothesis | — no observation — | pending | 0.50 |
| Glymphatic enhancement in awake states showing equal clearance benefits | Confirmatory evidence for hypothesis | — no observation — | pending | 0.50 |
| Long-term AQP4 modulation studies showing no cognitive protection | Confirmatory evidence for hypothesis | — no observation — | pending | 0.50 |
| OR2 agonist treatment worsening sleep quality despite microglial changes | Confirmatory evidence for hypothesis | — no observation — | pending | 0.50 |
| Orexin enhancement accelerating rather than slowing neurodegeneration | Confirmatory evidence for hypothesis | — no observation — | pending | 0.50 |
| Microglial depletion preventing orexin-mediated benefits | Confirmatory evidence for hypothesis | — no observation — | pending | 0.50 |
| A2A antagonists providing superior cognitive protection than agonists | Confirmatory evidence for hypothesis | — no observation — | pending | 0.50 |
| Metabolic enhancement without sleep improvement showing no neuroprotection | Confirmatory evidence for hypothesis | — no observation — | pending | 0.50 |
| Adenosine system manipulation having no effect on established neurodegeneration | Confirmatory evidence for hypothesis | — no observation — | pending | 0.50 |
| α2A agonists accelerating cognitive decline despite reducing tau pathology | Confirmatory evidence for hypothesis | — no observation — | pending | 0.50 |
| LC lesions preventing rather than promoting tau spread | Confirmatory evidence for hypothesis | — no observation — | pending | 0.50 |
| REM enhancement having no effect on established tau networks | Confirmatory evidence for hypothesis | — no observation — | pending | 0.50 |
| Circadian restoration without autophagy enhancement showing no benefits | Confirmatory evidence for hypothesis | — no observation — | pending | 0.50 |
| Autophagy enhancement in circadian-disrupted models providing full protection | Confirmatory evidence for hypothesis | — no observation — | pending | 0.50 |
| Clock gene manipulation worsening neurodegeneration despite improved autophagy | Confirmatory evidence for hypothesis | — no observation — | pending | 0.50 |
| Sleep spindle enhancement without memory improvement in MCI patients | Confirmatory evidence for hypothesis | — no observation — | pending | 0.50 |
| T-type channel modulation causing seizures or cardiac arrhythmias | Confirmatory evidence for hypothesis | — no observation — | pending | 0.50 |
| Spindle-independent memory consolidation pathways providing equal benefits | Confirmatory evidence for hypothesis | — no observation — | pending | 0.50 |
| Neurogenesis enhancement without cognitive benefits in human studies | Confirmatory evidence for hypothesis | — no observation — | pending | 0.50 |
| Hypocretin modulation disrupting rather than improving sleep architecture | Confirmatory evidence for hypothesis | — no observation — | pending | 0.50 |
| BDNF manipulation causing adverse neurological effects | Confirmatory evidence for hypothesis | — no observation — | pending | 0.50 |
🔮 Falsifiable Predictions (10)
pendingconf 50%
Glymphatic enhancement in awake states showing equal clearance benefits
Predicted outcome: Confirmatory evidence for hypothesis
Falsification: Failure of: Glymphatic enhancement in awake states showing equal clearance benefits
pendingconf 50%
Long-term AQP4 modulation studies showing no cognitive protection
Predicted outcome: Confirmatory evidence for hypothesis
Falsification: Failure of: Long-term AQP4 modulation studies showing no cognitive protection
pendingconf 50%
OR2 agonist treatment worsening sleep quality despite microglial changes
Predicted outcome: Confirmatory evidence for hypothesis
Falsification: Failure of: OR2 agonist treatment worsening sleep quality despite microglial changes
pendingconf 50%
Orexin enhancement accelerating rather than slowing neurodegeneration
Predicted outcome: Confirmatory evidence for hypothesis
Falsification: Failure of: Orexin enhancement accelerating rather than slowing neurodegeneration
pendingconf 50%
Microglial depletion preventing orexin-mediated benefits
Predicted outcome: Confirmatory evidence for hypothesis
Falsification: Failure of: Microglial depletion preventing orexin-mediated benefits
pendingconf 50%
A2A antagonists providing superior cognitive protection than agonists
Predicted outcome: Confirmatory evidence for hypothesis
Falsification: Failure of: A2A antagonists providing superior cognitive protection than agonists
pendingconf 50%
Metabolic enhancement without sleep improvement showing no neuroprotection
Predicted outcome: Confirmatory evidence for hypothesis
Falsification: Failure of: Metabolic enhancement without sleep improvement showing no neuroprotection
pendingconf 50%
Adenosine system manipulation having no effect on established neurodegeneration
Predicted outcome: Confirmatory evidence for hypothesis
Falsification: Failure of: Adenosine system manipulation having no effect on established neurodegeneration
pendingconf 50%
α2A agonists accelerating cognitive decline despite reducing tau pathology
Predicted outcome: Confirmatory evidence for hypothesis
Falsification: Failure of: α2A agonists accelerating cognitive decline despite reducing tau pathology
pendingconf 50%
Selective AQP4 upregulation without sleep improvement in transgenic models
Predicted outcome: Confirmatory evidence for hypothesis
Falsification: Failure of: Selective AQP4 upregulation without sleep improvement in transgenic models
📖 References (9)
- A three-dimensional human neural cell culture model of Alzheimer's disease.Choi SH et al.. Nature (2014)
- Als and Ftd: Insights into the disease mechanisms and therapeutic targets.Liscic RM. Eur J Pharmacol (2017)
- Lysosomal cholesterol activates mTORC1 via an SLC38A9-Niemann-Pick C1 signaling complex.Castellano BM et al.. Science (2017)
- Modulation by orexin A of spontaneous excitatory and inhibitory transmission in adult rat spinal substantia gelatinosa neurons.Wang C et al.. Biochemical and biophysical research communications (2018)
- Involvement of the Orexin 1 and 2 Receptors in Nucleus Incertus (NI) on Modulation of Spatial Reference Memory in the Morris Water Maze.Eslami F et al.. Archives of Razi Institute (2024)
- Mechanistic insights into influenza vaccine-associated narcolepsy.Ahmed SS et al.. Human vaccines & immunotherapeutics (2016)
- A comparative examination of thrombocyte/platelet immunity.F Ferdous et al.. Immunology letters (2015)
- Defining the consequences of genetic variation on a proteome-wide scale.Chick JM et al.. Nature (2016)
- Low Rates of Gastrointestinal and Non-Gastrointestinal Complications for Screening or Surveillance Colonoscopies in a Population-Based Study.Wang L et al.. Gastroenterology (2018)
Related Entities
▸Metadata
| status | proposed |
| _schema_version | 1 |
| hypothesis_type | None |
📊 Evidence Profile
Foundational
Evidence Balance
+0%
Certainty
100%
Debates
2
Incoming
4388
Outgoing
2613
0 supporting
0 contradicting
2 neutral
🌍 Provenance Graph
8 nodes, 14 edges
derives from (14)
hypothesis-h-8597755b→analysis-SDA-2026-04-01-gap-v2analysis-SDA-2026-04-01-gap-v2→hypothesis-h-41bc2d38hypothesis-h-41bc2d38→analysis-SDA-2026-04-01-gap-v2analysis-SDA-2026-04-01-gap-v2→hypothesis-h-de579cafhypothesis-h-de579caf→analysis-SDA-2026-04-01-gap-v2
▸ Show 9 more
analysis-SDA-2026-04-01-gap-v2→hypothesis-h-b7898b79hypothesis-h-b7898b79→analysis-SDA-2026-04-01-gap-v2analysis-SDA-2026-04-01-gap-v2→hypothesis-h-4113b0e8hypothesis-h-4113b0e8→analysis-SDA-2026-04-01-gap-v2analysis-SDA-2026-04-01-gap-v2→hypothesis-h-8597755banalysis-SDA-2026-04-01-gap-v2→hypothesis-h-8d270062hypothesis-h-8d270062→analysis-SDA-2026-04-01-gap-v2analysis-SDA-2026-04-01-gap-v2→hypothesis-h-6b84d8e2hypothesis-h-6b84d8e2→analysis-SDA-2026-04-01-gap-v2
🗣 Debate History2 sessions
gap_analysisWhat are the mechanisms underlying sleep disruption as cause and consequence of neurodegeneration?r4q=0.952026-04-01
gap_analysisWhat are the mechanisms underlying sleep disruption as cause and consequence of neurodegeneration?r4q=0.952026-04-01+0.000
This artifact has no version history yet.
Linked Artifacts (6988)
🧬 Related Hypotheses — same target / disease (20)
Night-phase orexin receptor antagonism rescues AD by restoring sleep-dependent clearance
Score: 0.758 · Target: HCRTR2 · neurodegeneration
Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration
Score: 0.924 · Target: NLRP3, CASP1, IL1B, PYCARD · neurodegeneration
APOE-Dependent Autophagy Restoration
Score: 0.895 · Target: MTOR · neurodegeneration
Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse
Score: 0.895 · Target: SLC16A1, SLC16A7, LDHA, PDHA1 · neurodegeneration
p38α Inhibitor and PRMT1 Activator Combination to Restore Physiological TDP-43 Phosphoryla
Score: 0.895 · Target: MAPK14/PRMT1 · neurodegeneration
SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence
Score: 0.893 · Target: SIRT1 · neurodegeneration
TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegeneration
Score: 0.892 · Target: TREM2 · neurodegeneration
Optimized Temporal Window for Metabolic Boosting Therapy Determines Success of Microglial
Score: 0.887 · Target: IFNG · neurodegeneration
TREM2-APOE Axis Dissociation for Selective DAM Activation
Score: 0.886 · Target: TREM2-APOE axis · neurodegeneration
Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation
Score: 0.882 · Target: HCRTR1/HCRTR2 · neurodegeneration
Complement Cascade Inhibition Synaptic Protection
Score: 0.867 · Target: — · neurodegeneration
TREM2 R47H Variant-Driven Metabolic Dysfunction as the Primary Trigger for Failed DAM Tran
Score: 0.862 · Target: NAMPT · neurodegeneration
H6: Aberrant eIF2α Phosphorylation Creates Stalled Translation State
Score: 0.856 · Target: EIF2S1, EIF2AK3/PERK, PPP1R15B, EIF2B · neurodegeneration
Senescent Cell ASM-Complement Cascade Intervention
Score: 0.852 · Target: SMPD1 · neurodegeneration
Prime Editing Precision Correction of APOE4 to APOE3 in Microglia
Score: 0.850 · Target: APOE · neurodegeneration
TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxicity in Alzheimer's Disease
Score: 0.847 · Target: TREM2 · neurodegeneration
Neutral Sphingomyelinase-2 Inhibition for Synaptic Protection in Neurodegeneration
Score: 0.844 · Target: SMPD3 · neurodegeneration
TYROBP (DAP12) Conditional Antagonism for Early-Stage Neuroprotection
Score: 0.844 · Target: TYROBP · neurodegeneration
miR-155/Interferon-gamma Feedback Loop as a Reversible Molecular Switch for Protective Mic
Score: 0.843 · Target: MIR155 · neurodegeneration
Hypothesis 7: SST-SST1R/Gamma Entrainment-Enhanced Astrocyte Secretome
Score: 0.839 · Target: SST, SSTR1, SSTR2 · neurodegeneration
Reference URLs
Embed this artifact
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
HTML iframe
<iframe src="http://scidex.ai/artifact/hypothesis-h-8597755b?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
Markdown link
[Orexin-Microglia Modulation Therapy](http://scidex.ai/artifact/hypothesis-h-8597755b)
Direct URL
http://scidex.ai/artifact/hypothesis-h-8597755b
Preview
🔄 Adjacent Artifacts
Recommended based on your interests
💬 Discussion
Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.